NMN and Altitude Performance: NAD+ for Oxygen Efficiency

NMN and altitude performance is a biologically plausible topic because lower oxygen availability makes mitochondrial efficiency, glucose handling, and recovery more important. However, the clinical question is narrower than the marketing claim: oral NMN has been shown to raise NAD-related measures in some human studies, but it has not yet been proven to improve acclimatization, oxygen saturation, acute mountain sickness, or endurance at altitude in a human randomized trial.

NMN and Altitude Performance: What the Research Actually Shows

The current evidence for NMN at altitude is indirect. The available studies examine NAD+ metabolism, insulin sensitivity, safety, and age-related physiology rather than hiking, climbing, cycling, or sleeping at high elevation. That distinction matters because a supplement can change a biomarker without producing a meaningful improvement in oxygen delivery or exercise capacity.

The strongest human evidence comes from metabolic studies. In a randomized trial of 25 overweight or obese postmenopausal women with prediabetes, 250 mg of NMN daily for 10 weeks increased skeletal-muscle insulin sensitivity by approximately 25% compared with placebo, without improving liver insulin sensitivity or body composition (Yoshino et al. (2021)). This is relevant to altitude because carbohydrate metabolism is often important during hypoxic exercise, but the participants were not exposed to altitude and performance outcomes were not tested.

Other human work supports short-term tolerability and biological activity. In healthy Japanese men, single oral doses of 100, 250, or 500 mg NMN were evaluated for clinical safety parameters and circulating nicotinamide metabolites; the study did not identify acute clinically meaningful safety concerns at those doses (Fukamizu et al. (2022)). A separate study in healthy adults with mild sleep disturbance found that chronic NMN supplementation elevated blood NAD-related measures, but it was not an altitude or athletic-performance trial (Igarashi et al. (2022)).

Preclinical evidence is broader but cannot be treated as proof for climbers. Long-term NMN administration improved several age-associated physiological measures in mice, including measures related to energy metabolism and activity, at doses far higher on a body-weight basis than typical human supplement use (Mills et al. (2016)). Mouse data are useful for generating hypotheses about NAD+ biology; they do not establish a human altitude dose or an altitude-performance benefit.

How NMN May Affect Altitude Performance Through NAD+ Biology

NAD+ is an essential coenzyme that helps cells turn nutrients into usable energy. It cycles between oxidized NAD+ and reduced NADH during glycolysis, the tricarboxylic-acid cycle, and mitochondrial oxidative phosphorylation. At altitude, reduced inspired oxygen lowers the oxygen gradient available for aerobic ATP production, so the body relies on coordinated changes in ventilation, circulation, substrate use, and mitochondrial metabolism.

NMN is a precursor in the NAD+ salvage pathway. Nicotinamide is recycled through nicotinamide phosphoribosyltransferase (NAMPT) to form nicotinamide mononucleotide, which is then converted to NAD+. NAMPT and NAD metabolism influence energy balance, cellular stress responses, and the activity of NAD+-dependent enzymes such as sirtuins and poly(ADP-ribose) polymerases (Garten et al. (2015)).

This mechanism helps explain why NMN and altitude performance is worth studying, but it also sets clear limits. NAD+ availability is only one component of exercise capacity. Hemoglobin concentration, plasma volume, pulmonary gas exchange, cardiac output, capillary blood flow, iron status, sleep, training history, energy intake, pacing, and the degree of hypoxic exposure can all dominate the real-world outcome.

Hypoxia also changes fuel preference. At a given workload, carbohydrate oxidation generally yields more ATP per unit of oxygen consumed than fat oxidation, although it is not automatically “better” in every setting because glycogen stores are finite. The muscle insulin-sensitivity finding from Yoshino et al. (2021) raises a reasonable hypothesis that NMN could influence substrate handling in some people, but it does not show improved respiratory exchange ratio, lactate threshold, VO2 max, or time to exhaustion at altitude.

For a deeper explanation of the cellular side of this question, see NMN and Mitochondria: How NAD+ Powers Cellular Energy Production. For the exercise-specific evidence base, our review of NMN and Exercise Capacity: How NAD+ Affects Endurance and Aerobic Performance separates mechanistic rationale from direct performance data.

NMN at Altitude: Dose, Form, and Evidence Compared

No evidence-based NMN dose has been established specifically for altitude exposure. The doses below describe what has been studied in the cited human and animal research, not a validated protocol for preventing altitude illness or increasing summit performance. Supplements should not replace ascent planning, acclimatization days, hydration, adequate carbohydrate intake, or clinician-guided preventive medication when appropriate.

Study context	Population	NMN exposure	Main measured outcome	What it means for altitude
Metabolic randomized trial	25 prediabetic postmenopausal women	250 mg/day for 10 weeks	About 25% greater skeletal-muscle insulin sensitivity versus placebo	Supports a metabolic hypothesis; no hypoxia or exercise-performance outcome
Acute clinical-parameter study	Healthy Japanese men	100, 250, or 500 mg orally	Nicotinamide-metabolite and safety measures	Supports short-term study of these doses, not altitude efficacy
Chronic NAD-related biomarker study	Healthy adults with mild sleep disturbance	Chronic oral supplementation	Elevated blood NAD-related measures	Biomarker change does not establish better oxygen use or acclimatization
Long-term animal study	Aging mice	High body-weight-based dosing	Multiple age-associated physiological measures	Preclinical support only; cannot be directly converted to a human altitude dose

Timing is similarly unsettled. Because the available studies did not test ascent schedules, there is no clinical basis for saying NMN should be started a specific number of days before travel, taken immediately before exertion, or used as a rescue strategy after symptoms begin. A product such as PEPAX NMN should be viewed as a dietary supplement intended to support NAD+ precursor intake, not as treatment for hypoxia or a substitute for medical assessment.

People sometimes combine NMN with other performance-focused supplements, but each claim should stand on its own evidence. Molecular hydrogen, for example, has a separate literature involving lactate, perceived exertion, and exercise outcomes; see Hydrogen Water and Endurance: Does H2 Improve VO2, Lactate, and Time to Exhaustion?. That does not mean a combination has been clinically tested for altitude performance.

Who May Benefit From NMN and Altitude Performance Strategies

The people most likely to benefit from NMN are not yet known because altitude-specific trials have not been completed. The best-supported human signal is in skeletal-muscle insulin sensitivity among prediabetic postmenopausal women, not in healthy young mountaineers or high-altitude workers. It would be inaccurate to extrapolate that result into a promise of improved oxygen efficiency for every traveler.

NMN may be of research interest for adults whose altitude goals overlap with metabolic health, aging, or endurance training. This includes older recreational hikers, people returning to aerobic training after inactivity, and individuals who want to understand NAD+ biology alongside established conditioning practices. Yet “research interest” is not the same as a demonstrated clinical benefit, especially when acute mountain sickness and impaired sleep at elevation can affect even well-trained people.

Endurance athletes may be especially tempted by the phrase “oxygen efficiency.” In practical physiology, efficiency is not a single biomarker: it can refer to economy at a fixed pace, oxygen uptake at a given workload, lactate accumulation, power at threshold, or the ability to maintain output under hypoxia. None of the listed NMN studies measured these outcomes at altitude, so athletes should rely first on training, pacing, iron sufficiency, carbohydrate planning, and a gradual ascent.

People with diabetes, pregnancy, significant cardiovascular, kidney, or liver disease, active cancer treatment, or a history of severe altitude illness should seek individualized medical advice before using supplements as part of a high-altitude plan. This is not because the cited studies prove harm in these groups; rather, those populations were not adequately represented in the available NMN evidence. Symptoms such as severe headache, confusion, breathlessness at rest, worsening cough, loss of coordination, or inability to walk straight require prompt descent and medical evaluation rather than more supplementation.

Cardiorespiratory fitness remains more predictive and more actionable than unproven NAD+ optimization. Our article on VO2 Max and Longevity: Why Cardiorespiratory Fitness Predicts Lifespan explains why training adaptations and fitness assessment are central to both performance and long-term health.

Practical NMN and Altitude Performance Takeaways

The practical approach is to treat NMN as an optional, unproven adjunct rather than an altitude intervention. The following points align with the current level of evidence:

• Do not expect NMN to prevent acute mountain sickness, raise oxygen saturation, or replace acclimatization; these outcomes have not been demonstrated in human NMN trials.
• Recognize the most specific human result: 250 mg/day for 10 weeks improved skeletal-muscle insulin sensitivity in 25 prediabetic postmenopausal women, not altitude exercise performance.
• If using NMN, avoid changing multiple supplements immediately before a major ascent; otherwise, tolerability and effects are difficult to interpret.
• Prioritize proven altitude preparation: progressive ascent, conservative pacing, sufficient energy intake, sleep planning, weather contingencies, and attention to symptoms.
• Use performance metrics that matter: resting heart rate, perceived exertion, pace at a fixed effort, sleep quality, gastrointestinal tolerance, and—where available—oxygen saturation trends.
• Choose products with a clearly stated NMN amount and avoid treating a supplement label as evidence of clinical efficacy. PEPAX NMN is best considered within that evidence-aware framework.

NMN and Altitude Performance: Bottom Line

NMN and altitude performance is a credible research hypothesis, not a proven performance strategy. Human studies show that oral NMN can influence NAD-related biology and, in one specific metabolic population, improve skeletal-muscle insulin sensitivity; they do not show better acclimatization, oxygen efficiency, or endurance at altitude. Until direct randomized trials measure outcomes such as SpO2, acute mountain sickness scores, lactate, VO2, and time to exhaustion, the evidence quality for altitude-specific claims remains low.

---

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels in healthy subjects with mild sleep disturbance." NPJ Aging. 2022;8(1):5. [Source]
3. Fukamizu Y, et al. "Effects of orally administered nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Scientific Reports. 2022;12:6134. [Source]
4. Mills KF, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metabolism. 2016;24(6):795–806. [Source]
5. Garten A, et al. "Physiological and pathophysiological roles of NAMPT and NAD metabolism." Nature Reviews Endocrinology. 2015;11(9):535–546. [Source]

---

---